Skip to main content Skip to section navigation Skip to footer
Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & Patients
    • Clinical Trials
    • REFRαME
    • Patients
      • Patient Resources
      • Commitment To Patients
      • Compassionate Use Access
  • Science
    • Pipeline
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • News
    • News Releases
    • Presentation & Publication
    • Events
    • Events Audio Replays
  • Join Us
    • The Way We Work
    • Join Our Team
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • Events & Audio Replays
    • Email Alerts
  • Company Info
    • Company Profile
    • Management Team
    • Functional Leadership Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • Events & Audio Replays
  • Email Alerts
Apr 20, 2021 7:00 am EDT
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
Apr 15, 2021 7:00 am EDT
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
Apr 8, 2021 7:00 am EDT
Sutro Biopharma to Present at Two Upcoming Investor Conferences
Mar 22, 2021 7:00 am EDT
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Mar 18, 2021 7:00 am EDT
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
Feb 23, 2021 7:00 am EST
Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
Jan 21, 2021 7:00 am EST
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
Jan 5, 2021 7:00 am EST
Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Dec 11, 2020 4:01 pm EST
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Dec 8, 2020 9:10 pm EST
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • …
  • Page 22
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
Sutro Biopharma Corporate Site

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2025 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.